Genentech Roche launch plant in North Carolina
Genentech broke ground this week on a $700 million manufacturing facility in Holly Springs, North Carolina, marking the biotechnology company’s first East Coast production site. The 700,000-square-foot plant will focus on metabolic medicines, including next-generation treatments for obesity, and is expected to create more than 1,900 jobs in the state.
Jobs and Economic Impact
The facility will employ 400 workers once operational, with an additional 1,500 construction jobs during the development phase.
The project represents Genentech’s initial investment in North Carolina and is part of a broader $50 billion commitment to U.S. manufacturing, infrastructure, and research and development.
U.S. Rep. Deborah Ross attended the event and called it a milestone for the community. She acknowledged, “Investments like this one mean good-paying jobs for our residents, expanded opportunities for workers with a range of skills and education, and continued growth for the Research Triangle’s innovation ecosystem.”
North Carolina Governor Josh Stein also appeared at the ceremony, noting that the state has built a reputation as a favorable environment for biotech companies. He highlighted, “From our top-tier research universities to our world-class workforce, North Carolina has exactly what companies need to succeed.”
Facility Details and Regional Strategy
The 100-acre site includes space for future expansion, allowing Genentech to grow and adapt to its evolving needs. The company selected Holly Springs for its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area.
Related: ProRank and Goodwork Merge to Transform Healthcare Talent
Construction is underway, with completion targeted for 2029. The facility will incorporate modern biomanufacturing technologies, advanced automation, and digital capabilities designed to increase production capacity while maintaining sustainable operations.
Mayor Sean Mayefskie said the development is expected to boost the local economy, particularly for small businesses.
The timing of the announcement coincides with broader federal efforts to encourage domestic pharmaceutical manufacturing. Company officials said they appreciate the Department of Commerce’s work to address regulatory delays that can slow facility development in the United States.
Founded in 1976, Genentech operates as a member of the Roche Group and is headquartered in South San Francisco, California. The company develops and manufactures medicines for serious and life-threatening conditions. The Holly Springs site represents a notable geographic expansion as the company seeks to diversify its production network, enabling it to better serve patients and reduce supply chain vulnerabilities.
The new facility is expected to contribute to the company’s growth and innovation, as well as strengthen the local and state economies.
